InterCure Ltd., a leading player in the medical cannabis industry, is headquartered in Israel (IL) and operates extensively across Europe and North America. Founded in 2010, the company has achieved significant milestones, establishing itself as a pioneer in the cultivation and distribution of high-quality cannabis products. InterCure focuses on developing innovative therapeutic solutions, offering a range of unique cannabis-based products that cater to various medical needs. Their commitment to quality and compliance sets them apart in a competitive market, positioning them as a trusted name in the industry. With a robust market presence and a dedication to advancing cannabis research, InterCure Ltd. continues to shape the future of medical cannabis, making substantial contributions to patient care and wellness.
How does InterCure Ltd.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
InterCure Ltd.'s score of 25 is lower than 63% of the industry. This can give you a sense of how well the company is doing compared to its peers.
InterCure Ltd., headquartered in Israel (IL), currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. Furthermore, there are no documented reduction targets or climate pledges associated with the company. As of now, InterCure Ltd. does not inherit emissions data from any parent or related organizations, meaning all information is self-reported. The company has not established any Science-Based Targets Initiative (SBTi) reduction targets or other significant climate commitments. In the context of the industry, it is essential for companies to actively engage in climate action and set measurable targets to reduce their carbon footprint. However, without specific data or commitments, InterCure Ltd.'s current climate strategy remains unclear.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
InterCure Ltd. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
